Trehalose/sodium hyaluronate eye drops in post-cataract ocular surface disorders.
Cataract surgery
Dry eye
Post-operative
Trehalose/sodium hyaluronate/carbomer eye drops
Journal
International ophthalmology
ISSN: 1573-2630
Titre abrégé: Int Ophthalmol
Pays: Netherlands
ID NLM: 7904294
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
20
10
2020
accepted:
15
04
2021
pubmed:
7
5
2021
medline:
18
8
2021
entrez:
6
5
2021
Statut:
ppublish
Résumé
Prospective, randomised, open-label, comparative study to evaluate efficacy of trehalose/sodium hyaluronate eye drops for post-operative discomfort and tear film stability in patients undergoing cataract surgery. Patients with healthy ocular surface, subclinical, or mild dry eye were enrolled. Tear breakup time (TBUT), Schirmer test, dry eye symptoms, corneal fluorescein staining (CFS), and ocular surface disease (OSDI) evaluation were performed pre-operatively and at two and four weeks after surgery. Patients were assigned to receive trehalose/sodium hyaluronate eye drops b.i.d (Group A), or 0.9% unpreserved sodium chloride eye drops b.i.d for 4 weeks (Group B). One hundred and thirty-five patients were randomised, 66 patients in Group A (73.2 ± 4.5 years) and 69 patients in Group B (74.3 ± 3.8 years), 60.8% females. Fifteen patients (8 Group A) were lost at follow-up. Pre-operatively, no between-group differences were observed, and TBUT increased in Group A between the pre-operative and 2 and 4 week evaluations and was higher in group A than in Group B at 4 weeks. Schirmer test and CFS showed an improvement only in Group A four weeks post-operatively. In Group A an improvement was observed after two and four weeks in foreign body and puncture sensation, whilst a difference in blinking discomfort was observed after four weeks. In Group B we observed an improvement in puncture sensation two and four weeks after surgery. Mean OSDI scores differences between the two groups were significant at four weeks. Trehalose/sodium hyaluronate eye drops were effective in reducing signs and symptoms of dry eye and improving tear film stability.
Identifiants
pubmed: 33956256
doi: 10.1007/s10792-021-01869-z
pii: 10.1007/s10792-021-01869-z
pmc: PMC8364531
doi:
Substances chimiques
Ophthalmic Solutions
0
Hyaluronic Acid
9004-61-9
Trehalose
B8WCK70T7I
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
3065-3071Informations de copyright
© 2021. The Author(s).
Références
Clin Ophthalmol. 2019 Jul 09;13:1157-1163
pubmed: 31371913
Int Ophthalmol. 2019 Feb;39(2):419-429
pubmed: 29392638
Jpn J Ophthalmol. 2012 Mar;56(2):113-8
pubmed: 22298313
Ther Clin Risk Manag. 2015 Apr 13;11:595-603
pubmed: 25926736
Cornea. 2018 Jul;37(7):893-898
pubmed: 29504953
J Cataract Refract Surg. 2015 Aug;41(8):1699-704
pubmed: 26432128
Optometry. 2011 Jan;82(1):38-43
pubmed: 21146792
Clin Ophthalmol. 2011;5:577-81
pubmed: 21654884
Clin Ophthalmol. 2018 Jul 20;12:1293-1300
pubmed: 30050282
Curr Opin Ophthalmol. 2016 Jan;27(1):24-30
pubmed: 26569526
BMC Ophthalmol. 2015 Mar 20;15:28
pubmed: 25880685
Korean J Ophthalmol. 2009 Jun;23(2):65-73
pubmed: 19568353
J Exp Biol. 2008 Sep;211(Pt 18):2899-900
pubmed: 18775926
Int Ophthalmol. 2019 Jun;39(6):1345-1353
pubmed: 29926365
Cornea. 2008 Aug;27(7):855
pubmed: 18650678
Am J Ophthalmol. 2016 Mar;163:122-131.e2
pubmed: 26685791
Br J Ophthalmol. 2002 Feb;86(2):181-4
pubmed: 11815344
PLoS One. 2013 Nov 12;8(11):e78657
pubmed: 24265705
Ocul Surf. 2017 Jul;15(3):366-403
pubmed: 28736338
Cornea. 2018 Jun;37(6):734-739
pubmed: 29543662
J Cataract Refract Surg. 2015 Apr;41(4):756-63
pubmed: 25487027
Jpn J Ophthalmol. 2004 Jul-Aug;48(4):321-7
pubmed: 15295655
Int Ophthalmol. 2018 Oct;38(5):2021-2030
pubmed: 28822028